GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CPIX · Jun 30, 2020

CUMBERLAND PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-20-012738General Corporate
Revenue growth20thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

-17.12% · CORE · VALID

Inventory pressure65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

79.47% · OPTIONAL · VALID

Gross margin15thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

72.81% · CORE · VALID

Operating margin40thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-16.47% · CORE · VALID

R&D intensity65thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

14.81% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History61 statesSelf-history eligible
Period transition

What moved in the state?

Growth Increased
Previous
-30.01%
Current
-17.12%
Delta
12.89%
Inventory Pressure Decreased
Previous
97.83%
Current
79.47%
Delta
-18.37%
Margin Decreased
Previous
80.38%
Current
72.81%
Delta
-7.58%
Profitability Increased
Previous
-22.16%
Current
-16.47%
Delta
5.69%
R And D Intensity Decreased
Previous
20.68%
Current
14.81%
Delta
-5.87%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.